List of Locametz drug patents

Locametz is owned by Aaa Usa Novartis.

Locametz contains Gallium Ga-68 Gozetotide.

Locametz has a total of 1 drug patent out of which 0 drug patents have expired.

Locametz was authorised for market use on 23 March, 2022.

Locametz is available in powder;intravenous dosage forms.

Locametz can be used as for use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer.

The generics of Locametz are possible to be released after 15 August, 2028.

LOCAMETZ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11369590 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

Do you want to check out LOCAMETZ patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Mar 23, 2025

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 23 March, 2022

Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

LOCAMETZ family patents

26

United States

8

Japan

6

European Union

2

New Zealand

2

China

1

Poland

1

Spain

1

Hong Kong

1

Israel

1

Canada

1

Portugal

1

Denmark

1

Australia

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in